Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Advances and Challenges in Uveal Melanoma Immunotherapy
Yihang Fu, Wei Xiao, Yuxiang Mao
Cancers (2022) Vol. 14, Iss. 13, pp. 3094-3094
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Modulating T Cell Responses by Targeting CD3
Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1189-1189
Open Access | Times Cited: 41
Integrating single-cell analysis and machine learning to create glycosylation-based gene signature for prognostic prediction of uveal melanoma
Jian-Lan Liu, Pengpeng Zhang, Fang Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 40
Heterogeneity and molecular landscape of melanoma: implications for targeted therapy
Yasaman Zohrab Beigi, Hossein Lanjanian, Reyhane Fayazi, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 8
Uveal melanoma: Recent advances in immunotherapy
Francesco Saverio Sorrentino, Francesco De Rosa, Patrick Di Terlizzi, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 1, pp. 23-31
Open Access | Times Cited: 6
More than Just Skin-Deep: A Review of Imaging’s Role in Guiding CAR T-Cell Therapy for Advanced Melanoma
Conor M. Prendergast, Kathleen M. Capaccione, Egesta Lopci, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 992-992
Open Access | Times Cited: 13
Integrated analyses of prognostic and immunotherapeutic significance of EZH2 in uveal melanoma
Junfang Li, Yifei Zhang, Yang Qiu, et al.
Methods (2025) Vol. 234, pp. 242-252
Closed Access
Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial
Mohamed A. Gouda, Abdulrazzak Zarifa, Yali Yang, et al.
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 1, pp. 82-88
Open Access
Unlocking the Promise of Antitumor Hyperthermia‐Immunotherapy with Spiky Surface Topology
Muyue Yang, Yan Yu, Tongxin Ge, et al.
Advanced Science (2025)
Open Access
Unravelling the Molecular Pathways of Feline Diffuse Iris Melanoma Progression
David Kayes, B. Blacklock, Robert I. McGeachan, et al.
Research Square (Research Square) (2025)
Closed Access
Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review
Majid Banimohammad, Parsa Khalafi, Danial Gholamin, et al.
Exploration of Targeted Anti-tumor Therapy (2025)
Open Access
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma
Kamil Synoradzki, Natalia Paduszyńska, Małgorzata Solnik, et al.
Current Oncology (2024) Vol. 31, Iss. 2, pp. 778-800
Open Access | Times Cited: 4
Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances
Merve Kulbay, Nicolas Tuli, M. R. Mazza, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 108-108
Open Access
A Review and Comparison of Immune-Checkpoint Inhibitors in the Treatment of Metastatic Uveal Melanoma
Benyamin Alam, Amir Reza Akbari, Ahmed Ageed, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 885-885
Open Access
Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations
Liu Hon, Zhou Run‐hua, Jingxuan Pan, et al.
Pigment Cell & Melanoma Research (2024) Vol. 37, Iss. 3, pp. 411-425
Closed Access | Times Cited: 3
How to Manage a Patient with Ocular Metastases?
Juliette Thariat, Laurys Boudin, Olivier Loria, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3044-3044
Open Access | Times Cited: 15
Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort
Nuno Jorge Lamas, Sandra Lassalle, Arnaud Martel, et al.
Pathology (2023) Vol. 55, Iss. 7, pp. 929-944
Open Access | Times Cited: 7
Cooperative phototherapy based on bimodal imaging guidance for the treatment of uveal melanoma
Tong Huang, Xinzhi Xu, Cheng Chen, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 6
Selamectin increases cisplatin sensitivity by inhibiting cisplatin-resistant genes expression and autophagy in uveal melanoma
Jie He, Jili Chen, Jianfeng Shen
Biochemical and Biophysical Research Communications (2023) Vol. 661, pp. 75-81
Closed Access | Times Cited: 5
Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases
Abin Sajan, Samuel B. Fordyce, Andrew Sideris, et al.
Diagnostics (2023) Vol. 13, Iss. 11, pp. 1836-1836
Open Access | Times Cited: 5
Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
Yuanyuan Hu, Jiayang Cai, Meng Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma
Ru Zhu, Yuting Chen, Bowen Wang, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis
Wenting Tang, Qiong Shao, Zhanwen He, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Regional chemotherapy for uveal melanoma liver metastases
Yang-Xu Tao, Jingting Luo, Yang Li, et al.
International Journal of Ophthalmology (2023) Vol. 16, Iss. 2, pp. 293-300
Open Access | Times Cited: 3
Construction and Verification of the Molecular Subtype and a Novel Prognostic Signature Based on Inflammatory Response-Related Genes in Uveal Melanoma
Feng Zhang, Yan Deng, Dong Wang, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 861-861
Open Access | Times Cited: 2
Multiple epigenetic modification profiles reveal the tumor immune microenvironment and clinical outcomes of uveal melanoma
Xinshuai Nan, Yuchen Liu, Yuzhen Gao, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top